Cargando…

BRAF抑制剂治疗非小细胞肺癌的进展

In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer (NSCLC), drugs targeting epidermal growth factor receptor (EGFR) has been widely used in clinical practice, it is of milestone significance. V-raf murine sarcoma viral oncogene homolog B1 (BRAF)...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973409/
https://www.ncbi.nlm.nih.gov/pubmed/27760604
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.13
_version_ 1783326624367771648
collection PubMed
description In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer (NSCLC), drugs targeting epidermal growth factor receptor (EGFR) has been widely used in clinical practice, it is of milestone significance. V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors targeted at BRAF gene have obviously clinical efficacy to specific advantages populations with little side-effect, and be well tolerated. It is discovered recently that drug resistance also exists in BRAF inhibitors like other targeted drugs, the mechanism of drug resistance is being studied. In this paper, a review were performed in the mechanism, clinical application, adverse reactions and the drug resistance of BRAF inhibitors.
format Online
Article
Text
id pubmed-5973409
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59734092018-07-06 BRAF抑制剂治疗非小细胞肺癌的进展 Zhongguo Fei Ai Za Zhi 综述 In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer (NSCLC), drugs targeting epidermal growth factor receptor (EGFR) has been widely used in clinical practice, it is of milestone significance. V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors targeted at BRAF gene have obviously clinical efficacy to specific advantages populations with little side-effect, and be well tolerated. It is discovered recently that drug resistance also exists in BRAF inhibitors like other targeted drugs, the mechanism of drug resistance is being studied. In this paper, a review were performed in the mechanism, clinical application, adverse reactions and the drug resistance of BRAF inhibitors. 中国肺癌杂志编辑部 2016-10-20 /pmc/articles/PMC5973409/ /pubmed/27760604 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.13 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
BRAF抑制剂治疗非小细胞肺癌的进展
title BRAF抑制剂治疗非小细胞肺癌的进展
title_full BRAF抑制剂治疗非小细胞肺癌的进展
title_fullStr BRAF抑制剂治疗非小细胞肺癌的进展
title_full_unstemmed BRAF抑制剂治疗非小细胞肺癌的进展
title_short BRAF抑制剂治疗非小细胞肺癌的进展
title_sort braf抑制剂治疗非小细胞肺癌的进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973409/
https://www.ncbi.nlm.nih.gov/pubmed/27760604
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.13
work_keys_str_mv AT brafyìzhìjìzhìliáofēixiǎoxìbāofèiáidejìnzhǎn
AT brafyìzhìjìzhìliáofēixiǎoxìbāofèiáidejìnzhǎn
AT brafyìzhìjìzhìliáofēixiǎoxìbāofèiáidejìnzhǎn